Metric | Fiscal 2024 Results | Fiscal 2025 Results | Fiscal 2026 Outlook | ||||||||
Adj. Revenue | $1,617M | $1,660M | Low to mid-single digit growth | ||||||||
Adj. EBITDA Margin | 22.8% | 24% | 25.5% to 26.5% | ||||||||
Adj. EPS | $2.78 | $3.64 | $3.90 to $4.35 | ||||||||
Free Cash Flow | $114M | $126M | Approximately $200M |
Three Months Ended April 30, | Year Ended April 30, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Revenue, net | $ | 442,579 | $ | 468,461 | $ | 1,677,609 | $ | 1,872,987 | |||||||||||||||
Costs and expenses: | |||||||||||||||||||||||
Cost of sales | 110,941 | 123,345 | 431,380 | 579,722 | |||||||||||||||||||
Operating and administrative expenses | 229,767 | 252,062 | 947,437 | 1,013,520 | |||||||||||||||||||
Impairment of goodwill(3) | — | — | — | 108,449 | |||||||||||||||||||
Restructuring and related charges | 12,490 | 11,008 | 25,561 | 63,041 | |||||||||||||||||||
Amortization of intangible assets | 12,909 | 13,264 | 51,822 | 55,994 | |||||||||||||||||||
Total costs and expenses | 366,107 | 399,679 | 1,456,200 | 1,820,726 | |||||||||||||||||||
Operating income | 76,472 | 68,782 | 221,409 | 52,261 | |||||||||||||||||||
As a % of revenue | 17.3 | % | 14.7 | % | 13.2 | % | 2.8 | % | |||||||||||||||
Interest expense | (11,270) | (11,411) | (52,547) | (49,003) | |||||||||||||||||||
Net foreign exchange transaction (losses) gains | (826) | 530 | (8,142) | (2,959) | |||||||||||||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale(3) | (13,580) | (3,642) | (23,340) | (183,389) | |||||||||||||||||||
Other income (expense), net | 1,469 | (257) | 5,498 | (3,957) | |||||||||||||||||||
Income (loss) before taxes | 52,265 | 54,002 | 142,878 | (187,047) | |||||||||||||||||||
(Benefit) provision for income taxes | (15,828) | 28,737 | 58,717 | 13,272 | |||||||||||||||||||
Effective tax rate | -30.3 | % | 53.2 | % | 41.1 | % | -7.1 | % | |||||||||||||||
Net income (loss) | $ | 68,093 | $ | 25,265 | $ | 84,161 | $ | (200,319) | |||||||||||||||
As a % of revenue | 15.4 | % | 5.4 | % | 5.0 | % | -10.7 | % | |||||||||||||||
Earnings (loss) per share | |||||||||||||||||||||||
Basic | $ | 1.27 | $ | 0.46 | $ | 1.56 | $ | (3.65) | |||||||||||||||
Diluted(4) | $ | 1.25 | $ | 0.46 | $ | 1.53 | $ | (3.65) | |||||||||||||||
Weighted average number of common shares outstanding | |||||||||||||||||||||||
Basic | 53,683 | 54,591 | 54,054 | 54,945 | |||||||||||||||||||
Diluted(4) | 54,458 | 55,356 | 54,830 | 54,945 | |||||||||||||||||||
Notes: | ||
(1) The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission. | ||
(2) All amounts are approximate due to rounding. | ||
(3) Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale For the three months and year ended April 30, 2025 and 2024, we recorded net pretax (loss) gain on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows: |
Three Months Ended April 30, | Year Ended April 30, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Wiley Edge | $ | (74) | $ | 1,275 | $ | (14,852) | $ | (19,401) | |||||||||||||||
University Services | (13,428) | (5,636) | (12,578) | (107,048) | |||||||||||||||||||
CrossKnowledge | (78) | 719 | 4,119 | (55,440) | |||||||||||||||||||
Tuition Manager | — | — | 120 | (1,500) | |||||||||||||||||||
Sale of assets | — | — | (149) | — | |||||||||||||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | $ | (13,580) | $ | (3,642) | $ | (23,340) | $ | (183,389) | |||||||||||||||
As previously announced in fiscal year 2024, we executed a plan to divest non-core businesses included in our Held for Sale or Sold segment, including University Services, Wiley Edge, and CrossKnowledge. These three businesses met the held-for-sale criteria starting in the first quarter of fiscal year 2024. We measured each disposal group at the lower of carrying value or fair value less costs to sell prior to its disposition. On January 1, 2024, we completed the sale of University Services. On June 5, 2025, Wiley entered into an agreement to sell the Seller Note, the fiscal year 2026 earnout, the TVG Investment, and agreed on the fiscal year 2025 earnout for total cash consideration of $119.5 million, which was fully paid in June 2025. In the year ended April 30, 2025, due to the process of selling these assets, as well as third-party customer consents, working capital adjustments, and changes in the costs to sell, we recognized an additional net loss on sale and impairments of assets of $12.6 million. In the three months ended April 30, 2025, we recognized an additional net loss of $13.4 million. On May 31, 2024, we completed the sale of Wiley Edge, with the exception of its India operations which sold on August 31, 2024. Upon the completion of the sale, we recognized a net loss of $14.9 million in the year ended April 30, 2025 primarily due to subsequent changes in the fair value less costs to sell including reducing the fair value of the contingent consideration in the form of an earnout from $15.0 million to zero in the third quarter of fiscal year 2025, partially offset by the sale of the India operations. On August 31, 2024, we completed the sale of CrossKnowledge. On May 31, 2023, we completed the sale of Tuition Manager. In the second quarter of fiscal year 2025, we sold a facility which was reflected in Technology, property, and equipment, net in our Unaudited Condensed Consolidated Statements of Financial Position. Impairment of goodwill In fiscal year 2024, we reorganized our segments and recorded pretax noncash goodwill impairments of $108.4 million which included $81.7 million related to Wiley Edge, $11.4 million related to University Services, and $15.3 million related to CrossKnowledge. | |||||||||||||||||||||||
(4) In calculating diluted net loss per common share for the year ended April 30, 2024, our diluted weighted average number of common shares outstanding excludes the effect of unvested restricted stock units and other stock awards as the effect was antidilutive. This occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. |
Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS | |||||||||||||||||||||||
Three Months Ended April 30, | Year Ended April 30, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
US GAAP Earnings (Loss) Per Share - Diluted | $ | 1.25 | $ | 0.46 | $ | 1.53 | $ | (3.65) | |||||||||||||||
Adjustments: | |||||||||||||||||||||||
Impairment of goodwill | — | — | — | 1.90 | |||||||||||||||||||
Restructuring and related charges | 0.14 | 0.16 | 0.36 | 0.85 | |||||||||||||||||||
Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments (3) | (0.01) | 0.01 | 0.08 | 0.02 | |||||||||||||||||||
Amortization of acquired intangible assets (4) | 0.15 | 0.02 | 0.76 | 0.68 | |||||||||||||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5) | 0.18 | 0.04 | 0.38 | 2.81 | |||||||||||||||||||
Held for Sale or Sold segment Adjusted Net (Income) Loss (5) | — | (0.03) | 0.05 | (0.42) | |||||||||||||||||||
Income tax adjustments | (0.34) | 0.55 | 0.48 | 0.54 | |||||||||||||||||||
EPS impact of using weighted-average dilutive shares for adjusted EPS calculation (6) | — | — | — | 0.05 | |||||||||||||||||||
Non-GAAP Adjusted Earnings Per Share - Diluted | $ | 1.37 | $ | 1.21 | $ | 3.64 | $ | 2.78 | |||||||||||||||
Reconciliation of US GAAP Income (Loss) Before Taxes to Non-GAAP Adjusted Income Before Taxes | |||||||||||||||||||||||
(amounts in thousands) | Three Months Ended April 30, | Year Ended April 30, | |||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
US GAAP Income (Loss) Before Taxes | $ | 52,265 | $ | 54,002 | $ | 142,878 | $ | (187,047) | |||||||||||||||
Pretax Impact of Adjustments: | |||||||||||||||||||||||
Impairment of goodwill | — | — | — | 108,449 | |||||||||||||||||||
Restructuring and related charges | 12,490 | 11,008 | 25,561 | 63,041 | |||||||||||||||||||
Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments (3) | — | 815 | 5,590 | 1,903 | |||||||||||||||||||
Amortization of acquired intangible assets (4) | 12,908 | 13,324 | 51,864 | 57,874 | |||||||||||||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5) | 13,580 | 3,642 | 23,340 | 183,389 | |||||||||||||||||||
Held for Sale or Sold segment Adjusted (Income) Loss Before Taxes (5) | — | (2,409) | 3,578 | (30,661) | |||||||||||||||||||
Non-GAAP Adjusted Income Before Taxes | $ | 91,243 | $ | 80,382 | $ | 252,811 | $ | 196,948 | |||||||||||||||
Reconciliation of US GAAP Income Tax (Benefit) Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate | |||||||||||||||||||||||
US GAAP Income Tax (Benefit) Provision | $ | (15,828) | $ | 28,737 | $ | 58,717 | $ | 13,272 | |||||||||||||||
Income Tax Impact of Adjustments (7) | |||||||||||||||||||||||
Impairment of goodwill | — | 255 | — | 2,953 | |||||||||||||||||||
Restructuring and related charges | 4,633 | 2,425 | 5,947 | 15,662 | |||||||||||||||||||
Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments (3) | 571 | 471 | 1,170 | 582 | |||||||||||||||||||
Amortization of acquired intangible assets (4) | 4,720 | 11,459 | 10,231 | 20,127 | |||||||||||||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (5) | 3,715 | 1,197 | 2,368 | 26,908 | |||||||||||||||||||
Held for Sale or Sold segment Adjusted Tax (Provision) Benefit (5) | — | (622) | 807 | (7,140) | |||||||||||||||||||
Income Tax Adjustments: | |||||||||||||||||||||||
Impact of valuation allowance on the US GAAP effective tax rate (8) | 18,776 | (30,249) | (26,008) | (30,249) | |||||||||||||||||||
Impact of change in certain US state tax rates in 2025 (8) | (117) | — | (117) | — | |||||||||||||||||||
Non-GAAP Adjusted Income Tax Provision | $ | 16,470 | $ | 13,673 | $ | 53,115 | $ | 42,115 | |||||||||||||||
US GAAP Effective Tax Rate | -30.3 | % | 53.2 | % | 41.1 | % | -7.1 | % | |||||||||||||||
Non-GAAP Adjusted Effective Tax Rate | 18.1 | % | 17.0 | % | 21.0 | % | 21.4 | % |
Notes: | |||||
(1) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission. | |||||
(2) All amounts are approximate due to rounding. | |||||
(3) In fiscal year 2023 due to the closure of our operations in Russia, the Russia entity was deemed substantially liquidated. The formal liquidation was completed in the fourth quarter of fiscal year 2025. In the three months and year ended April 30, 2025, we wrote off an additional $1.1 million and $1.4 million, respectively, of cumulative translation adjustments in earnings. In the three months and year ended April 30, 2024, we wrote off an additional $0.2 million and $1.0 million, respectively, of cumulative translation adjustments in earnings. These amounts are reflected in Net foreign exchange transaction (losses) gains on our Condensed Consolidated Statements of Net Income (Loss). | |||||
(4) Reflects the amortization of intangible assets established on the opening balance sheet for an acquired business. This includes the amortization of intangible assets such as developed technology, customer relationships, tradenames, etc., which is reflected in the "Amortization of intangible assets" line in the Condensed Consolidated Statements of Net Income (Loss). It also includes the amortization of acquired product development assets, which is reflected in Cost of sales in the Condensed Consolidated Statements of Net Income (Loss). |
(5) For the three months and year ended April 30, 2025 and 2024, we recorded net pretax loss (gain) on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows: | |||||||||||||||||||||||
Three Months Ended April 30, | Year Ended April 30, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Wiley Edge | $ | 74 | $ | (1,275) | $ | 14,852 | $ | 19,401 | |||||||||||||||
University Services | 13,428 | 5,636 | 12,578 | 107,048 | |||||||||||||||||||
CrossKnowledge | 78 | (719) | (4,119) | 55,440 | |||||||||||||||||||
Tuition Manager | — | — | (120) | 1,500 | |||||||||||||||||||
Sale of assets | — | — | 149 | — | |||||||||||||||||||
Net pretax loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | $ | 13,580 | $ | 3,642 | $ | 23,340 | $ | 183,389 | |||||||||||||||
For the three months and year ended April 30, 2025 and 2024, we recorded income tax benefit (provision) on sale of businesses, assets, and impairment charges related to assets held-for-sale as follows: | |||||||||||||||||||||||
Three Months Ended April 30, | Year Ended April 30, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Wiley Edge | $ | 263 | $ | 890 | $ | (1,054) | $ | 890 | |||||||||||||||
University Services | 3,109 | 307 | 3,109 | 25,643 | |||||||||||||||||||
CrossKnowledge | 344 | — | 344 | — | |||||||||||||||||||
Tuition Manager | — | — | (30) | 374 | |||||||||||||||||||
Sale of assets | — | — | — | — | |||||||||||||||||||
Benefit on sale of businesses, assets, and impairment charges related to assets held-for-sale | $ | 3,715 | $ | 1,197 | $ | 2,368 | $ | 26,908 | |||||||||||||||
In addition, our Adjusted EPS excludes the Adjusted Net Income or Loss of our Held for Sale or Sold segment. | |||||||||||||||||||||||
(6) Represents the impact of using diluted weighted-average number of common shares outstanding (55.7 million for the year ended April 30, 2024) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. | |||||||||||||||||||||||
(7) For the three months and year ended April 30, 2025 and 2024, respectively, substantially all of the tax impact was from deferred taxes. | |||||||||||||||||||||||
(8) In fiscal year 2024, due to temporary differences in the US, our deferred taxes reversed from a net deferred tax liability position to a net deferred tax asset position. Due to losses in the US resulting from impairments, restructuring, and acceleration of amortization expense on capitalized software, we concluded it was more-likely-than-not that all or a portion of our deferred tax asset may not be realized. As a result, we established a valuation allowance of $30.2 million. During fiscal year 2025 we increased this valuation allowance by $26.0 million, because of an increase in the US net deferred tax asset attributable primarily to interest expense disallowance and intangible and fixed assets. In connection with the increase in certain US state tax apportionment factors and state rate changes in 2025, we recorded income tax expense of $0.1 million for the three months and year ended April 30, 2025. |
Three Months Ended April 30, | Year Ended April 30, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Net Income (Loss) | $ | 68,093 | $ | 25,265 | $ | 84,161 | $ | (200,319) | |||||||||||||||
Interest expense | 11,270 | 11,411 | 52,547 | 49,003 | |||||||||||||||||||
(Benefit) provision for income taxes | (15,828) | 28,737 | 58,717 | 13,272 | |||||||||||||||||||
Depreciation and amortization | 36,681 | 47,613 | 147,126 | 176,989 | |||||||||||||||||||
Non-GAAP EBITDA | 100,216 | 113,026 | 342,551 | 38,945 | |||||||||||||||||||
Impairment of goodwill | — | — | — | 108,449 | |||||||||||||||||||
Restructuring and related charges | 12,490 | 11,008 | 25,561 | 63,041 | |||||||||||||||||||
Net foreign exchange transaction losses (gains) | 826 | (530) | 8,142 | 2,959 | |||||||||||||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | 13,580 | 3,642 | 23,340 | 183,389 | |||||||||||||||||||
Other (income) expense, net | (1,469) | 257 | (5,498) | 3,957 | |||||||||||||||||||
Held for Sale or Sold segment Adjusted EBITDA (2) | — | (2,409) | 3,578 | (32,148) | |||||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 125,643 | $ | 124,994 | $ | 397,674 | $ | 368,592 | |||||||||||||||
Adjusted EBITDA Margin | 28.4 | % | 28.3 | % | 24.0 | % | 22.8 | % |
Notes: | ||
(1) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission. | ||
(2) Our Non-GAAP Adjusted EBITDA excludes the Held for Sale or Sold segment Non-GAAP Adjusted EBITDA. |
% Change | |||||||||||||||||||||||
Three Months Ended April 30, | Favorable (Unfavorable) | ||||||||||||||||||||||
2025 | 2024 | Reported | Constant Currency | ||||||||||||||||||||
Research: | |||||||||||||||||||||||
Revenue, net | |||||||||||||||||||||||
Research Publishing | $ | 243,061 | $ | 233,455 | 4 | % | 4 | % | |||||||||||||||
Research Solutions | 37,660 | 37,577 | 0 | % | 0 | % | |||||||||||||||||
Total Revenue, net | $ | 280,721 | $ | 271,032 | 4 | % | 3 | % | |||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 75,168 | $ | 68,282 | 10 | % | 10 | % | |||||||||||||||
Depreciation and amortization | 22,303 | 25,513 | 13 | % | 13 | % | |||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 97,471 | $ | 93,795 | 4 | % | 4 | % | |||||||||||||||
Adjusted EBITDA margin | 34.7 | % | 34.6 | % | |||||||||||||||||||
Learning: | |||||||||||||||||||||||
Revenue, net | |||||||||||||||||||||||
Academic | $ | 100,146 | $ | 98,908 | 1 | % | 1 | % | |||||||||||||||
Professional | 61,712 | 71,237 | -13 | % | -14 | % | |||||||||||||||||
Total Revenue, net | $ | 161,858 | $ | 170,145 | -5 | % | -5 | % | |||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 58,715 | $ | 57,682 | 2 | % | 1 | % | |||||||||||||||
Depreciation and amortization | 10,948 | 16,358 | 33 | % | 33 | % | |||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 69,663 | $ | 74,040 | -6 | % | -6 | % | |||||||||||||||
Adjusted EBITDA margin | 43.0 | % | 43.5 | % | |||||||||||||||||||
Held for Sale or Sold: | |||||||||||||||||||||||
Total Revenue, net | $ | — | $ | 27,284 | # | # | |||||||||||||||||
Non-GAAP Adjusted Operating Income | $ | — | $ | 2,409 | # | # | |||||||||||||||||
Depreciation and amortization | — | — | # | # | |||||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | — | $ | 2,409 | # | # | |||||||||||||||||
Adjusted EBITDA margin | 0.0 | % | 8.8 | % | |||||||||||||||||||
Corporate Expenses: | |||||||||||||||||||||||
Non-GAAP Adjusted Corporate Expenses | $ | (44,921) | $ | (48,583) | 8 | % | 7 | % | |||||||||||||||
Depreciation and amortization | 3,430 | 5,742 | 40 | % | 40 | % | |||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | (41,491) | $ | (42,841) | 3 | % | 3 | % | |||||||||||||||
Consolidated Results: | |||||||||||||||||||||||
Revenue, net | $ | 442,579 | $ | 468,461 | -6 | % | -6 | % | |||||||||||||||
Less: Held for Sale or Sold Segment (3) | — | (27,284) | # | # | |||||||||||||||||||
Adjusted Revenue, net | $ | 442,579 | $ | 441,177 | 0 | % | 0 | % | |||||||||||||||
Operating Income | $ | 76,472 | $ | 68,782 | 11 | % | 11 | % | |||||||||||||||
Adjustments: | |||||||||||||||||||||||
Restructuring charges | 12,490 | 11,008 | -13 | % | -13 | % | |||||||||||||||||
Held for Sale or Sold Segment Adjusted Operating Income (3) | — | (2,409) | # | # | |||||||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 88,962 | $ | 77,381 | 15 | % | 15 | % | |||||||||||||||
Adjusted Operating Income margin | 20.1 | % | 17.5 | % | |||||||||||||||||||
Depreciation and amortization | 36,681 | 47,613 | 23 | % | 23 | % | |||||||||||||||||
Less: Held for Sale or Sold Segment depreciation and amortization (3) | — | — | # | # | |||||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 125,643 | $ | 124,994 | 1 | % | 0 | % | |||||||||||||||
Adjusted EBITDA margin | 28.4 | % | 28.3 | % |
Notes: | ||
(1) The supplementary information included in this press release for the three months and year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission. | ||
(2) All amounts are approximate due to rounding. | ||
(3) Our Adjusted Revenue, Adjusted Operating Income and Adjusted EBITDA excludes the impact of our Held for Sale or Sold segment Revenue, Adjusted Operating Income or Loss and Adjusted EBITDA results. | ||
# Variance greater than 100% |
% Change | |||||||||||||||||||||||
Year Ended April 30, | Favorable (Unfavorable) | ||||||||||||||||||||||
2025 | 2024 | Reported | Constant Currency | ||||||||||||||||||||
Research: | |||||||||||||||||||||||
Revenue, net | |||||||||||||||||||||||
Research Publishing | $ | 922,553 | $ | 892,784 | 3 | % | 3 | % | |||||||||||||||
Research Solutions | 152,906 | 149,921 | 2 | % | 2 | % | |||||||||||||||||
Total Revenue, net | $ | 1,075,459 | $ | 1,042,705 | 3 | % | 3 | % | |||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 255,580 | $ | 237,763 | 7 | % | 8 | % | |||||||||||||||
Depreciation and amortization | 89,302 | 93,422 | 4 | % | 5 | % | |||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 344,882 | $ | 331,185 | 4 | % | 5 | % | |||||||||||||||
Adjusted EBITDA margin | 32.1 | % | 31.8 | % | |||||||||||||||||||
Learning: | |||||||||||||||||||||||
Revenue, net | |||||||||||||||||||||||
Academic | $ | 333,693 | $ | 323,541 | 3 | % | 3 | % | |||||||||||||||
Professional | 251,075 | 251,198 | 0 | % | 0 | % | |||||||||||||||||
Total Revenue, net | $ | 584,768 | $ | 574,739 | 2 | % | 2 | % | |||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 174,850 | $ | 142,733 | 23 | % | 22 | % | |||||||||||||||
Depreciation and amortization | 43,900 | 57,696 | 24 | % | 24 | % | |||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 218,750 | $ | 200,429 | 9 | % | 9 | % | |||||||||||||||
Adjusted EBITDA margin | 37.4 | % | 34.9 | % | |||||||||||||||||||
Held for Sale or Sold: | |||||||||||||||||||||||
Total Revenue, net | $ | 17,382 | $ | 255,543 | -93 | % | -93 | % | |||||||||||||||
Non-GAAP Adjusted Operating (Loss) Income | $ | (3,578) | $ | 28,711 | # | # | |||||||||||||||||
Depreciation and amortization | — | 3,437 | # | # | |||||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | (3,578) | $ | 32,148 | # | # | |||||||||||||||||
Adjusted EBITDA margin | -20.6 | % | 12.6 | % | |||||||||||||||||||
Corporate Expenses: | |||||||||||||||||||||||
Non-GAAP Adjusted Corporate Expenses | $ | (179,882) | $ | (185,456) | 3 | % | 3 | % | |||||||||||||||
Depreciation and amortization | 13,924 | 22,434 | 38 | % | 38 | % | |||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | (165,958) | $ | (163,022) | -2 | % | -2 | % | |||||||||||||||
Consolidated Results: | |||||||||||||||||||||||
Revenue, net | $ | 1,677,609 | $ | 1,872,987 | -10 | % | -10 | % | |||||||||||||||
Less: Held for Sale or Sold Segment (3) | (17,382) | (255,543) | -93 | % | -93 | % | |||||||||||||||||
Adjusted Revenue, net | $ | 1,660,227 | $ | 1,617,444 | 3 | % | 3 | % | |||||||||||||||
Operating Income | $ | 221,409 | $ | 52,261 | # | # | |||||||||||||||||
Adjustments: | |||||||||||||||||||||||
Restructuring charges | 25,561 | 63,041 | 59 | % | 59 | % | |||||||||||||||||
Impairment of goodwill | — | 108,449 | # | # | |||||||||||||||||||
Held for Sale or Sold Segment Adjusted Operating Loss (Income) (3) | 3,578 | (28,711) | # | # | |||||||||||||||||||
Non-GAAP Adjusted Operating Income | $ | 250,548 | $ | 195,040 | 28 | % | 29 | % | |||||||||||||||
Adjusted Operating Income margin | 15.1 | % | 12.1 | % | |||||||||||||||||||
Depreciation and amortization | 147,126 | 176,989 | 17 | % | 17 | % | |||||||||||||||||
Less: Held for Sale or Sold depreciation and amortization (3) | — | (3,437) | # | # | |||||||||||||||||||
Non-GAAP Adjusted EBITDA | $ | 397,674 | $ | 368,592 | 8 | % | 8 | % | |||||||||||||||
Adjusted EBITDA margin | 24.0 | % | 22.8 | % |
# Variance greater than 100% |
April 30, 2025 | April 30, 2024 | ||||||||||
Assets: | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 85,882 | $ | 83,249 | |||||||
Accounts receivable, net | 228,410 | 224,198 | |||||||||
Inventories, net | 22,875 | 26,219 | |||||||||
Prepaid expenses and other current assets | 102,717 | 85,954 | |||||||||
Current assets held-for-sale | — | 34,422 | |||||||||
Total current assets | 439,884 | 454,042 | |||||||||
Technology, property and equipment, net | 162,125 | 192,438 | |||||||||
Intangible assets, net | 595,044 | 615,694 | |||||||||
Goodwill | 1,121,505 | 1,091,368 | |||||||||
Operating lease right-of-use assets | 66,128 | 69,074 | |||||||||
Other non-current assets | 306,780 | 283,719 | |||||||||
Non-current assets held-for-sale | — | 19,160 | |||||||||
Total assets | $ | 2,691,466 | $ | 2,725,495 | |||||||
Liabilities and shareholders' equity: | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 60,948 | $ | 55,659 | |||||||
Accrued royalties | 109,765 | 97,173 | |||||||||
Short-term portion of long-term debt | 10,000 | 7,500 | |||||||||
Contract liabilities | 462,693 | 483,778 | |||||||||
Accrued employment costs | 93,117 | 96,980 | |||||||||
Short-term portion of operating lease liabilities | 18,282 | 18,294 | |||||||||
Other accrued liabilities | 66,051 | 76,266 | |||||||||
Current liabilities held-for-sale | — | 37,632 | |||||||||
Total current liabilities | 820,856 | 873,282 | |||||||||
Long-term debt | 789,435 | 767,096 | |||||||||
Accrued pension liability | 71,899 | 70,832 | |||||||||
Deferred income tax liabilities | 105,145 | 97,186 | |||||||||
Operating lease liabilities | 81,482 | 94,386 | |||||||||
Other long-term liabilities | 70,443 | 71,760 | |||||||||
Long-term liabilities held-for-sale | — | 11,237 | |||||||||
Total liabilities | 1,939,260 | 1,985,779 | |||||||||
Shareholders' equity | 752,206 | 739,716 | |||||||||
Total liabilities and shareholders' equity | $ | 2,691,466 | $ | 2,725,495 |
Notes: | ||
(1) The supplementary information included in this press release for April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission. |
Year Ended April 30, | |||||||||||
2025 | 2024 | ||||||||||
Operating activities: | |||||||||||
Net income (loss) | $ | 84,161 | $ | (200,319) | |||||||
Impairment of goodwill | — | 108,449 | |||||||||
Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | 23,340 | 183,389 | |||||||||
Amortization of intangible assets | 51,822 | 55,994 | |||||||||
Amortization of product development assets | 16,610 | 22,835 | |||||||||
Amortization of cloud computing arrangements | 1,081 | 1,210 | |||||||||
Depreciation and amortization of technology, property, and equipment | 78,694 | 98,160 | |||||||||
Other noncash charges | 101,808 | 106,507 | |||||||||
Net change in operating assets and liabilities | (154,925) | (168,587) | |||||||||
Net cash provided by operating activities | 202,591 | 207,638 | |||||||||
Investing activities: | |||||||||||
Additions to technology, property, and equipment | (61,473) | (76,080) | |||||||||
Product development spending | (15,228) | (17,262) | |||||||||
Businesses acquired in purchase transactions, net of cash acquired | (3,602) | (3,116) | |||||||||
Net cash transferred related to the sale of businesses and assets | (7,642) | (1,771) | |||||||||
Acquisitions of publication rights and other | (6,073) | (8,414) | |||||||||
Net cash used in investing activities | (94,018) | (106,643) | |||||||||
Financing activities: | |||||||||||
Net debt borrowings | 13,509 | 27,767 | |||||||||
Cash dividends | (76,101) | (76,964) | |||||||||
Purchases of treasury shares | (60,421) | (45,050) | |||||||||
Other | (2,317) | (12,974) | |||||||||
Net cash used in financing activities | (125,330) | (107,221) | |||||||||
Effects of exchange rate changes on cash, cash equivalents and restricted cash | 3,146 | (1,493) | |||||||||
Change in cash, cash equivalents and restricted cash for period | (13,611) | (7,719) | |||||||||
Cash, cash equivalents and restricted cash - beginning | 99,543 | 107,262 | |||||||||
Cash, cash equivalents and restricted cash - ending | $ | 85,932 | $ | 99,543 | |||||||
CALCULATION OF NON-GAAP FREE CASH FLOW LESS PRODUCT DEVELOPMENT SPENDING (2) | |||||||||||
Year Ended April 30, | |||||||||||
2025 | 2024 | ||||||||||
Net cash provided by operating activities | $ | 202,591 | $ | 207,638 | |||||||
Less: Additions to technology, property, and equipment | (61,473) | (76,080) | |||||||||
Less: Product development spending | (15,228) | (17,262) | |||||||||
Free cash flow less product development spending | $ | 125,890 | $ | 114,296 |
Notes: | ||
(1) The supplementary information included in this press release for the year ended April 30, 2025 is preliminary and subject to change prior to the filing of our upcoming Annual Report on Form 10-K with the Securities and Exchange Commission. | ||
(2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplemental information. |